Dual Antiplatelet Therapy Across Clinical Indications — Ischemic Outcomes, Bleeding Risks, and Treatment Strategies: Scoping Review with ☸️SAIMSARA

Name: SAIMSARA Evidence Object vascular::DAPT_PM
Creator: SAIMSARA
License: https://saimsara.com/license/

SAIMSARA

doi:10.62487/saimsara0eb77a90

SAIMSARA Journal

Machine-Readable Science • ISSN 3054-3991

Dual Antiplatelet Therapy Across Clinical Indications — Ischemic Outcomes, Bleeding Risks, and Treatment Strategies: Scoping Review with ☸️SAIMSARA

Cardiac & Vascular Health

Issue 1, Volume 1, 2026

Chat with this issue

DOI: 10.62487/saimsara0eb77a90

Editorial note

• Last update: 2026-11-11 12:47:08

What is this paper about

When does dual antiplatelet therapy prevent life-threatening ischemic events—and when does the bleeding risk outweigh the benefit? Drawing on 1,090 scientific references across coronary, cerebrovascular, and peripheral interventions, this review reveals the evidence behind treatment choices, optimal duration, and personalized strategies—explore the full review to discover what the research shows.

Human-verified editorial review Verified by World ID proof-of-human. This editorial layer was submitted from a SAIMSARA account verified as a unique human.

Generated with SAIMSARA v5.4

Abstract: To map the supplied evidence on DAPT across clinical indications, synthesizing its ischemic and bleeding outcomes, treatment duration, individualized selection, perioperative management, and implementation challenges, while distinguishing direct comparative evidence from observational and experimental findings. The review uses 1090 references and builds its evidence map from 5437 original studies with 42127523 total participants/sample observations (topic-deduplicated ΣN). The mapped evidence indicates that dual antiplatelet therapy is best understood as an indication- and time-dependent trade-off between ischemic protection and bleeding, not as a uniformly beneficial intervention. In selected coronary stent recipients, extending treatment beyond one year reduced stent thrombosis (0.4% versus 1.4%) but increased moderate or severe bleeding. Conversely, abbreviated regimens were associated with similar net adverse clinical events and less bleeding in patients at high bleeding risk, while early short-term DAPT after minor stroke or high-risk transient ischemic attack reduced recurrent stroke. These signals support individualized choice of agent, timing, and duration based on bleeding risk, platelet response, and CYP2C19 genotype. Future research should prioritize randomized comparisons of tailored DAPT strategies in peripheral, structural, and neurointerventional settings, where evidence remains largely observational.

Keywords: Dual antiplatelet therapy; Aspirin; P2Y12 inhibitors; Ischemic stroke; Acute coronary syndrome; Endovascular interventions; Bleeding risk; Thromboembolic complications; Antiplatelet therapy duration; Single antiplatelet therapy

Review Stats

Final search date and database lock: 2026-11-10 14:48:53 CET
Plan: Pro (expanded craft tokens; source: PubMed)
Source: PubMed
Total Abstracts/Papers: 9331
Downloaded Abstracts/Papers: 9331
Included original and non-original Abstracts/Papers (all): 8641
Included original Abstracts/Papers (Vote counting by direction of effect): 5437
Reference Index (links used in paper): 1090
Total participants/sample observations (topic deduplicated ΣN): 42127523

Get access to the full paper

Unlock the full evidence map

Full paper access includes the complete human-readable review, figures, reference index, PDF export, and machine-readable Evidence JSON download.
Evidence JSON can also be purchased separately if you only need the LLM-ready object for agent, AI, or RAG workflows.
Institutional or library access? Sign in with your institution email to open all available SAIMSARA papers under your institution access arrangement.
Need a SAIMSARA review on your own topic? ☸️Request.

Reference Index (1090)

[1] Dual Antiplatelet Therapy: A Concise Review for Clinicians. — https://doi.org/10.3390/life13071580
[2] Dual Antiplatelet Therapy in Patients With Minor Stroke Receiving Intravenous Thrombolysis. — https://doi.org/10.3389/fneur.2022.819896
[3] Dual antiplatelet therapy after TAVR: A drop in the bucket? — https://doi.org/10.1016/j.ijcard.2019.01.069
[4] Dual antiplatelet therapy with concomitant anticoagulation: current perspectives on triple therapy. — https://doi.org/10.5114/amsad/161172
[5] Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. — https://doi.org/10.1016/s0140-6736(14)62052-3
[6] Single vs dual antiplatelet therapy after left atrial appendage closure: A propensity score matching analysis. — https://doi.org/10.1016/j.hrthm.2024.12.007
[7] Dual antiplatelet therapy use by Canadian cardiac surgeons. — https://doi.org/10.1016/j.jtcvs.2015.08.066
[8] Individualization of Duration of Dual Antiplatelet Therapy after Coronary Stenting: A Comprehensive, Evidence-Based Review. — https://doi.org/10.3390/jcm12227144

Unlock the full paper to view the complete Reference Index.